COMPASS Pathways
CMPSBiotechUnited Kingdom · Est. 2016
0
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
0
Indications↗
Distinct diseases across all programs
11
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Key Events
Sep 5, 2026TrialA Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Aug 11, 2026TrialA Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression
Aug 11, 2026TrialA Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression
Mar 20, 2026TrialCOMP360: Psilocybin in Treatment-Resistant Depression
Jan 30, 2023TrialA Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Oct 12, 2022TrialEfficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
Jun 10, 2022TrialThe Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Aug 10, 2020TrialThe Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
Details
Company Info
Therapeutic Focus
PsychiatryOtherNeurologyOncologyMusculoskeletalGastroenterology
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)